Acima Private Wealth LLC Sells 430 Shares of Johnson & Johnson $JNJ

Acima Private Wealth LLC cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 5.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 7,096 shares of the company’s stock after selling 430 shares during the quarter. Acima Private Wealth LLC’s holdings in Johnson & Johnson were worth $1,084,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. GFG Capital LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Highline Wealth Partners LLC boosted its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. Finally, von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on JNJ shares. Bank of America lifted their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday. JPMorgan Chase & Co. boosted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Tuesday, September 16th. HSBC boosted their target price on Johnson & Johnson from $188.00 to $210.00 in a report on Tuesday, September 30th. Finally, Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $192.94.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $190.66 on Monday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $192.10. The business has a fifty day moving average price of $178.48 and a 200-day moving average price of $163.78. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The stock has a market capitalization of $459.16 billion, a P/E ratio of 20.39, a P/E/G ratio of 2.40 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion during the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s payout ratio is currently 55.61%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.